Search Results from Clinical Connection

 
Diabetes - Tustin CA (Metro Los Angeles)
Type 2 Diabetes with Chronic Constipation - El Paso TX
Type 2 Diabetes - Northridge CA (Metro Los Angeles)
Diabetes - Miami Lakes FL
Type 2 Diabetes - Redmond WA (Metro Seattle)
Diabetes - Escondido CA (Metro San Diego)
Diabetes Type II - Winter Haven FL
Obesity and Diabetes - Scottsdale AZ
Type II Diabetes Inadequately Controlled with Daily Basal Insulin - Sugar Land TX
Diabetes - Rutland VT
Diabetic Peripheral Neuropathy - Hamden CT (Metro New Haven)
Diabetic Peripheral Neuropathy (DPN) - Multiple Locations in the US
Diabetic Peripheral Neuropathy (DPN) - Hazelwood MO
Diabetic Peripheral Neuropathy (DPN) - Flossmoor IL
Diabetic Peripheral Neuropathy (DPN) - North Dartmouth MA
Diabetic Peripheral Neuropathy (DPN) - Tustin CA
Diabetic Kidney Disease - Waterbury CT
Type 2 Diabetes - Hamden CT (Metro New Haven)
Type 2 Diabetes - Waterbury CT
Diabetic Peripheral Neuropathy (DPN) - Winston Salem NC
Diabetic Kidney Disease - Kansas City MO
Type 2 Diabetes Mellitus, Chronic Kidney Disease - Kansas City MO
Diabetic Macular Edema (DME) - Multiple Locations in the US
Diabetic Macular Edema (DME) - Great Neck NY
Diabetic Macular Edema (DME) - Ladson SC
Diabetic Peripheral Neuropathy (DPN) - Fort Myers FL
Diabetic Peripheral Neuropathy (DPN) - Saint Charles MO
Diabetic Peripheral Neuropathy (DPN) - Monroe LA
Diabetic Peripheral Neuropathy (DPN) - Long Beach CA
Diabetic Peripheral Neuropathy (DPN) - Sterling Heights MI
Diabetic Peripheral Neuropathy (DPN) - Banning CA
Diabetic Macular Edema (DME) - Phoenix AZ
Type 2 Diabetes Weight Loss Study - Austin TX
Diabetic Peripheral Neuropathy (DPN) - Newton KS
Diabetic Peripheral Neuropathy (DPN) - San Antonio TX
Diabetic Peripheral Neuropathy (DPN) - Maitland FL
Diabetic Peripheral Neuropathy (DPN) - Hallandale FL
Diabetic Peripheral Neuropathy (DPN) - East Greenwich RI
Diabetic Peripheral Neuropathy (DPN) - El Dorado KS
Diabetic Peripheral Neuropathy (DPN) - Wichita KS
Diabetic Peripheral Neuropathy (DPN) - Anniston AL
Diabetic Peripheral Neuropathy (DPN) - Greensboro NC
Diabetic Macular Edema (DME) - Willow Park TX
NASH (Fatty Liver Disease) - Marrero LA (Metro New Orleans)
Diabetic Peripheral Neuropathy (DPN) - Meridian ID
Diabetic Peripheral Neuropathy (DPN) - Medford OR
Diabetic Macular Edema (DME) - The Woodlands TX
Diabetic Macular Edema (DME) - Winter Haven FL
Diabetic Macular Edema (DME) - Oak Forest IL
Diabetic Macular Edema (DME) - Lynchburg VA
Type 2 Diabetes - Waterbury CT
Diabetic Peripheral Neuropathy (DPN) - Seminole FL
Diabetic Peripheral Neuropathy (DPN) - Charleston SC
Diabetic Peripheral Neuropathy (DPN) - Fleming Island FL
Diabetic Peripheral Neuropathy (DPN) - Miami FL
Diabetic Peripheral Neuropathy (DPN) - Cincinnati OH
Diabetic Peripheral Neuropathy (DPN) - Bellevue WA
Diabetic Peripheral Neuropathy (DPN) - Henderson NV
Diabetic Peripheral Neuropathy (DPN) - New York NY
Diabetic Peripheral Neuropathy (DPN) - Phoenix AZ
Diabetic Peripheral Neuropathy (DPN) - Anderson SC
Diabetic Peripheral Neuropathy (DPN) - Evansville IN
Diabetic Macular Edema (DME) - Pompano Beach FL
Diabetic Peripheral Neuropathy (DPN) - Colorado Springs CO
Diabetic Peripheral Neuropathy (DPN) - The Villages FL
Diabetic Peripheral Neuropathy (DPN) - Orangeburg SC

Type 2 Diabetes Clinical Research

Diabetes mellitus is a chronic condition. It results in too much sugar in the blood stream due to the body's inability to efficiently use insulin. High blood sugar levels can eventually affect the circulatory, nervous and immune system. Complications may include kidney failure, heart attack and stroke. According to the CDC, approximately 34 million Americans have diabetes, with 90-95% of cases being Type 2. This more prevalent type occurs in adults.


The most common symptoms of Type 2 diabetes include excessive thirst and frequent urination. Patients also report having fatigue, numbness in the hands/feet, and a persistent feeling of hunger.


Numerous clinical trials are underway to aimed at improving treatment of Type 2 diabetes and quality of life for patients.


Those studying Type 2 diabetes have suggested that the problem lies in the insulin-producing beta cells of the pancreas. Therefore, Type 2 diabetes clinical trials now focus on increasing the efficiency of the beta cells.


The following is a list of oral anti-hyperglycemic drugs that can benefit type 2 diabetes patients.


Oral Hypoglycemic Medications

  • Sulfonylureas (glipizide, glyburide, gliclazide, glimepiride)
  • Meglitinides (repaglinide and nateglinide)
  • Biguanides (metformin)
  • Thiazolidinediones (rosiglitazone, pioglitazone)
  • αa-Glucosidase inhibitors (acarbose, miglitol, voglibose)
  • DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin)
  • SGLT2 inhibitors (dapagliflozin and canagliflozin)
  • Cycloset (bromocriptine)

References
  • https://www.cdc.gov/diabetes/basics/type2.html#:~:text=More%20than%2034%20million%20Americans,adults%20are%20also%20developing%20it
  • Griffin, Simon J., James K. Leaver, and Greg J. Irving. "Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes." Diabetologia 60.9 (2017): 1620-1629
  • Abdul-Ghani, Muhammad, and Ralph A. DeFronzo. "Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm." Diabetes Care 40.8 (2017): 1121-1127
  • Min, Thinzar, and Stephen C. Bain. "The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials." Diabetes Therapy 12.1 (2021): 143-157
  • Perkovic, Vlado, et al. "Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials." The Lancet Diabetes & Endocrinology 6.9 (2018): 691-704
  • Kohler, Sven, et al. "Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I–III clinical trials." Advances in Therapy 34.7 (2017): 1707-1726
  • Jabbour, Serge, et al. "Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials." Diabetes, Obesity and Metabolism 20.3 (2018): 620-628